Autolus Therapeutics plc (NASDAQ:AUTL) is a top pick for investors, with a consensus buy rating and a median price target of $10, representing a 495.24% upside potential. The company recently released positive data from its Phase 1 CARLYSLE trial, showing promising responses in patients with refractory systemic lupus erythematosus.

During the American Society of Hematology Annual Meeting, Autolus presented data from the CARLYSLE trial, where three patients achieved complete response and five patients met DORIS response criteria. The Chief Development Officer noted the encouraging high rate of DORIS responses induced by obe-cel.

Autolus Therapeutics plc (NASDAQ:AUTL) is a U.K.-based biopharmaceutical company focused on developing T-cell immunotherapies for cancer and autoimmune diseases. While AUTL shows promise, other AI stocks may offer greater upside potential with less downside risk.

Astera Labs (ALAB) saw a 13% decline due to profit-taking. Autolus Therapeutics plc (NASDAQ:AUTL) remains a standout stock with positive analyst ratings and promising clinical trial data.

Read more at Yahoo Finance: Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now?